Načítá se...
The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
INTRODUCTION: The biosimilar product Inflectra(®) has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in u...
Uloženo v:
| Vydáno v: | Prz Gastroenterol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Termedia Publishing House
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5672704/ https://ncbi.nlm.nih.gov/pubmed/29123576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2017.70468 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|